jeremiah@devisedesigns.com, Author at Corcept Therapeutics - Page 3 of 16

About jeremiah@devisedesigns.com

This author has not written his bio yet.
But we are proud to say that jeremiah@devisedesigns.com contributed 156 entries already.

Entries by jeremiah@devisedesigns.com

Metabolomic and Lipidomic Analysis of Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treated with the Selective Glucocorticoid Receptor Modulator Miricorilant

Kowdley et al. • 2024 • AASLD 2024 Congress

November 18, 2024

A Phase 1, Open-Label, Drug-Drug Interaction Study Designed to Evaluate the Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-gp Substrate Dabigatran Etexilate in Healthy Subjects

Kunta et al. • 2024 • AAPS 2024 Congress

October 31, 2024

Pharmacokinetics of the Selective Glucocorticoid Receptor Modulator Miricorilant in Healthy Volunteers and Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Custodio et al. • 2024 • EASL 2024 Congress

June 10, 2024

Hypercortisolism (Cushing syndrome)

Hypercortisolism Impact on Hypertension and Hyperglycemia and Beyond

Ralph A. DeFronzo • 2024 • Heart in Diabetes 2024
Posted with permission of the presenter.

June 7, 2024

Hypercortisolism (Cushing syndrome)

Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study

2024 • Heart in Diabetes 2024

June 7, 2024

Hypercortisolism (Cushing syndrome)

Results From Grace, a Phase 3 Double-blind, Randomized-withdrawal Study of the Selective Glucocorticoid Receptor Modulator Relacorilant for the Treatment of Endogenous Hypercortisolism (Cushing Syndrome)

2024 • ENDO 2024

June 3, 2024

Endocrinology, Hypercortisolism (Cushing syndrome)

Rapid Clinical Improvements in a Patient with Difficult-to-Control Type 2 Diabetes by Addressing Underlying Hypercortisolism with Mifepristone

2024 • AACE 2024

May 14, 2024

Final Overall Survival Data From a Randomized, Open-Label, Phase 2 Study of Relacorilant, a Selective Glucocorticoid Receptor Modulator, in Combination With Nab-Paclitaxel in Patients With Recurrent Platinum-Resistant Ovarian Cancer

Colombo et al. • 2024 • SGO 2024 Congress

March 18, 2024

MONARCH: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (NASH/MASH)

Alkhouri et al. • 2024 • NASH-TAG 2024 Congress

January 8, 2024

Miricorilant Reduced Liver Fat and Cardiometabolic Disease Markers in a Phase 1b, Open-Label Dose-Finding Study in Patients with Non-Alcoholic Steatohepatitis (NASH)

Alkhouri et al. • 2024 • NASH-TAG 2024 Congress

January 8, 2024

© 2024 Corcept Therapeutics, Incorporated

Privacy Notice | Terms of Use | Site Map | Your Privacy Choices | LinkedIn | Youtube

Your Privacy Choices